Loading
Colorectal and Anal Carcinomas / Gastrointestinal Tumor Research and Treatment · Journal article
Cancers · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of immune checkpoint inhibitor mechanisms and resistance in gastrointestinal malignancies. It summarizes emerging therapeutic approaches including next-generation checkpoint inhibitors, combination strategies, and biomarker development, but reports no original clinical trial results or efficacy data.
Journal article. Patients with gastrointestinal cancers, particularly those with microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors.
Most GI cancers remain resistant to PD-1/PD-L1-based immunotherapy due to suppressive tumor microenvironments, immune stromal exclusion, myeloid-driven immune suppression, defective antigen presentation, and adaptive immune resistance Alternative inhibitory pathways including LAG-3, TIGIT, TIM-3, and VISTA contribute to persistent T-cell dysfunction and resistance to checkpoint blockade ICIs have significantly changed treatment landscape for microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) gastrointestinal tumors
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies mechanistic barriers to immunotherapy in GI cancers and discusses evolving therapeutic strategies that may inform clinical trial design and patient selection approaches, but does not provide evidence for specific treatment recommendations.
A narrative review article summarizing mechanisms, resistance pathways, and emerging therapeutic strategies in GI cancer immunotherapy without presenting original clinical trial data or original research findings.
This review identifies mechanistic barriers to immunotherapy in GI cancers and discusses evolving therapeutic strategies that may inform clinical trial design and patient selection approaches, but does not provide evidence for specific treatment recommendations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint inhibitors (ICIs) have significantly changed the treatment landscape of several gastrointestinal (GI) malignancies, particularly microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors. However, most GI cancers remain resistant to current PD-1/PD-L1-based immunotherapy because of complex and highly suppressive tumor microenvironments characterized by immune stromal exclusion, myeloid-driven immune suppression, defective antigen presentation, and adaptive immune resistance mechanisms. Emerging evidence suggests that alternative inhibitory pathways, including lymphocyte activation gene-3 (LAG-3), T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and V-domain Ig suppressor of T-cell activation (VISTA), contribute substantially to persistent T-cell dysfunction and resistance to checkpoint blockade. This review summarizes the immune landscape of GI malignancies and discusses the biological mechanisms underlying resistance to current ICIs. We highlight the evolving role of next-generation immune checkpoints, ongoing clinical development of novel inhibitors, and emerging combination strategies involving chemotherapy, anti-angiogenic therapy, radiation, bispecific antibodies, and tumor microenvironment modulation. In addition, we discuss current limitations in biomarker development and the growing role of circulating tumor DNA, spatial immune profiling, and multi-omics approaches in patient selection. Finally, we explore future directions aimed at improving precision immunotherapy and expanding durable responses across GI cancers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.